Adam’s Take

Adam's Take Adam Feuerstein

A moment of truth arrives for CytoDyn’s Covid-19 drug. Don’t let spin obscure it

Adam's Take Adam Feuerstein

ASCO 2020 takeaways: AstraZeneca does a star turn, KRAS fizzles, and cell therapy shows progress

Adam's Take Adam Feuerstein

Moderna carries a big-boy market valuation now, so it shouldn’t act like a biotech penny stock

Adam's Take Adam Feuerstein

With high hopes for its Covid-19 vaccine, Moderna stock value requires nearly mythical leap of faith

Adam's Take Adam Feuerstein

CytoDyn says lead HIV drug was not filed for FDA approval, as previously claimed

Biotech Adam Feuerstein

CytoDyn CEO made $12M from his stock sale, and his explanation raises more questions

Adam's Take Adam Feuerstein

Without showing any data, CytoDyn touts treatment for Covid-19 as winner — while its CEO sells stock

Adam's Take Adam Feuerstein

Aytu Bioscience capitalizes on coronavirus antibody test demand, but the good times won’t last

Adam's Take Adam Feuerstein

Athersys pivots a stem cell therapy to Covid-19, but prior data offer little confidence

Adam's Take Adam Feuerstein

Biotech in the time of coronavirus: The return of mergers, acquisitions, and deals

Adam's Take Adam Feuerstein

Biotech in the time of coronavirus: Pondering the future of ‘JPM Week’

Adam's Take Adam Feuerstein

Biotech in the time of the coronavirus: With China returning to work, preclinical companies ramping back up

Adam's Take Adam Feuerstein

Biotech in the time of the coronavirus: Stocks are down, but optimistic investors see opportunities ahead

Adam's Take Adam Feuerstein

Biotech in the time of the coronavirus: Disruptions continue, but there’s some good news, too

Adam's Take Adam Feuerstein

Biotech in the time of the coronavirus: A semi-regular column on the outbreak’s impact on drug makers

Adam's Take Adam Feuerstein

Biotech, bracing for widespread coronavirus fallout, hopes for the best and prepares for the worst

Adam's Take Adam Feuerstein

TG Therapeutics cops to another blood cancer drug trial delay, as excuses wear thin

Adam's Take Adam Feuerstein

Allakos is running clinical trials in reverse, critics say, raising questions about its digestive disease drug

Adam's Take Adam Feuerstein

‘Pharma doesn’t like fish oil’: Wall Street funds sold Amarin after big win with heart drug

Adam's Take Adam Feuerstein

Investor impatience with Gilead reclamation project sparks acquisition chatter

Adam's Take Adam Feuerstein

If biotech had a Mount Rushmore, whose heads would you chisel in the granite?

Adam's Take Adam Feuerstein

As Biogen gets squishy on timing for an aducanumab filing, the clock is ticking

Adam's Take Adam Feuerstein

The truth about JPM: Less is more

Adam's Take Adam Feuerstein

All talk, no M&A makes for a down JPM Day

Adam's Take Adam Feuerstein

Two days into the ‘real’ start of 2020 and all those expected biotech buyouts are still MIA

Adam's Take Adam Feuerstein

Biotech 2020 preview: Takeover targets, notable drug launches, and genome editing readouts

Biotech Adam Feuerstein and Matthew Herper

STAT’s guide to the most important, beneficial drugs approved in the past decade

Adam's Take Adam Feuerstein

Maraganore victorious in best biopharma CEO tally; Vounatsos tops worst list

Adam's Take Adam Feuerstein

And now, your nominees for worst biopharma CEO of 2019. Let the voting begin!